- Heartburn Slideshow: Foods to Eat, Foods to Avoid
- 10 Facts About the Amazing Brain
- Weight Gain Shockers Slideshow Pictures
- What is mycophenolate mofetil-oral, and how does it work (mechanism of action)?
- What brand names are available for mycophenolate mofetil-oral?
- Is mycophenolate mofetil-oral available as a generic drug?
- Do I need a prescription for mycophenolate mofetil-oral?
- What are the side effects of mycophenolate mofetil-oral?
- What is the dosage for mycophenolate mofetil-oral?
- Which drugs or supplements interact with mycophenolate mofetil-oral?
- Is mycophenolate mofetil-oral safe to take if I'm pregnant or breastfeeding?
- What else should I know about mycophenolate mofetil-oral?
What is the dosage for mycophenolate mofetil-oral?
Mycophenolate mofetil should be given to patients as soon as possible following organ transplantation. Mycophenolate mofetil is recommended to be administered on an empty stomach, except in stable renal transplant patients in whom it can be administered with food if necessary.
- Adults: The recommended dose is 1 g administered orally or intravenously (over no less than 2 hours) twice a day.
- Pediatrics (3 months to 18 years of age): The recommended dose of the oral suspension is 600 mg/m2 administered twice daily (maximum daily dose of 2 g/10 ml). Patients with a body surface area of 1.25 m2 to 1.5 m2 may be administered capsules at a dose of 750 mg twice daily. Patients with a body surface area >1.5 m2 may be dosed with capsules or tablets at a dose of 1 g twice daily.
- Adults: The recommended dose is 1.5 g twice daily administered intravenously over no less than 2 hours or 1.5 g orally twice daily.
- Adults: The recommended dose is 1 g twice daily administered intravenously over no less than 2 hours or 1.5 g orally twice daily.
- Geriatrics (elderly patients): The recommended oral dose is 1 g twice daily for kidney transplant patients, 1.5 g twice daily for heart transplant patients, and 1 g twice daily administered intravenously or 1.5 g twice daily administered orally in liver transplant patients.
Which drugs or supplements interact with mycophenolate mofetil-oral?
Co-administration of acyclovir (Zovirax) or ganciclovir (Cytovene, Vitrasert, Zirgan) and mycophenolate mofetil may cause an increase in blood levels of mycophenolate mofetil and the interacting drug since these drugs compete with each other for elimination via the kidneys.
Antacids containing magnesium or aluminum hydroxide may decrease MPA blood levels. If combination use is necessary, administration of the two medications must be separated by several hours.
Proton pump inhibitors (PPIs) such as lansoprazole (Prevacid), pantoprazole (Protonix), and omeprazole (Prilosec) have been shown to reduce MPA blood levels. This effect may be due to a decrease in mycophenolate mofetil solubility caused by reduced acid secretion in the stomach caused by PPIs.
Cyclosporine (Sandimmune) may decrease MPA blood levels. Cyclosporine inhibits multidrug-resistant-associated protein 2 (MRP-2) transporter in the biliary tract, and this prevents the excretion of MPA into bile and elimination from the body.
Mycophenolate mofetil may decrease the effectiveness of some oral contraceptives (birth control pills). Combining mycophenolate mofetil with birth control pills should be done cautiously, and additional contraceptive barriers (such as condoms) should be used.
Sevelamer (Renvela) may decrease MPA blood levels. Sevelamer and other calcium free phosphate binders that are used for treating patients with kidney disease should not be administered with mycophenolate mofetil. If combination treatment is necessary, sevelamer and other calcium free phosphate binders must be given two hours after mycophenolic acid administration.
Norfloxacin (Noroxin) and metronidazole (Flagyl), two antibiotics, may decrease MPA blood levels. Use of these antibiotics with mycophenolate mofetil is not recommended. Other antibiotics that may also decrease MPA levels in the blood are ciprofloxacin (Cipro), amoxicillin plus clavulanic acid (Augmentin), and rifampin (Rifadin, Rimactane).
Probenecid may cause an increase in MPA blood levels by inhibiting its
excretion via renal tubular secretion.
Quick GuidePrescription Drug Abuse: Know The Warning Signs
Report Problems to the Food and Drug Administration
You are encouraged to report negative side effects of prescription drugs to the FDA. Visit the FDA MedWatch website or call 1-800-FDA-1088.
Need help identifying pills and medications?
Use the pill identifier tool on RxList.